Nanoparticle-based delivery of self-amplifying RNA

Affiliations

Kenneth Lundstrom. Gene Ther. 2020 May.

. 2020 May;27(5):183-185.

doi: 10.1038/s41434-020-0132-1. Epub 2020 Feb 28.

No abstract available

References

1. Lundstrom K. Self-amplifying RNA virus vectors: clinical applications in cancer drug delivery. Exp Opin Biol Ther. 2019;16:1027.
1. Lundstrom K. Self-replicating RNA viruses for RNA therapeutics. Molecules. 2018;23:E3310. https://doi.org/10.3390/molecules23123310 . - DOI - PubMed
1. Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet. 2017;389:505. - DOI
1. Galanis E, Hartmann LC, Cliby W, Peethambaram PP, Long HJ, Kaur JS, et al. Phase I trial of intraperitoneal (IP) administration of a measles virus (MV) derivative expressing the human carcinoembryonic antigen (CEA) in recurrent ovarian cancer (OvCa). J Clin Oncol. 2008;26(15S):5538.Abs. - DOI
1. Dispenzieri A, Tong C, La Plant B, Lacy MQ, Laumann K, Dingli D, et al. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. Leukemia. 2017;31:2791. - DOI